Three new commercial health plans, including one of the top five national providers of health insurance, has opted to provide coverage for Prolaris, from Myriad Genetics, Salt Lake City. Prolaris is a genetic test that directly measures tumor cell growth that, when paired with both prostate-specific antigen (PSA) and Gleason, offers an accurate assessment of how aggressively that cancer will progress over the next 10 years.
Nicole Lambert, Myriad Genetics.
“We are exceptionally pleased to see continued expansion in coverage for Prolaris which will provide greater access for patients,” says Nicole Lambert, president of Myriad International, oncology and women’s health. “Approximately 60% percent of men with prostate cancer now have access to prognostic testing and we look forward to the day when every man who is facing difficult treatment decisions has access to testing through their health plan.”
In combination, these three health plans cover approximately 26 million commercial lives, bringing total commercial coverage for Prolaris up to 55 million lives.
For more information, visit Myriad Genetics.
